Reliability of Resting-state Electrophysiology in Fragile X Syndrome

Overview

Journal Biomark Neuropsychiatry

Date 2024 May 31

PMID 38817342

Authors

Rui Liu

Ernest V Pedapati

Lauren M Schmitt

Rebecca C Shaffer

Elizabeth G Smith

Kelli C Dominick

Lisa A DeStefano

Grace Westerkamp

Paul Horn

John A Sweeney

Craig A Erickson

Affiliations

Soon will be listed here.

Abstract

Objective: Fragile X Syndrome (FXS) is the leading monogenic cause of intellectual disability and autism spectrum disorder. Currently, there are no established biomarkers for predicting and monitoring drug effects in FXS, and no approved therapies are available. Previous studies have shown electrophysiological changes in the brain using electroencephalography (EEG) in individuals with FXS and animal models. These changes may be influenced by drug therapies. In this study, we aimed to assess the reliability of resting-state EEG measures in individuals with FXS, which could potentially serve as a biomarker for drug discovery.

Methods: We collected resting-state EEG data from 35 individuals with FXS participating in placebo-controlled clinical trials (23 males, 12 females; visit age mean+/-std 25.6 +/-8.3). The data were analyzed for various spectral features using intraclass correlation analysis to evaluate test-retest reliability. The intervals between EEG recordings ranged from same-day measurements to up to six weeks apart.

Results: Our results showed high reliability for most spectral features, with same-day reliability exceeding 0.8. Features of interest demonstrated ICC values of 0.60 or above at longer intervals. Among the features, alpha band relative power exhibited the highest reliability.

Conclusion: These findings indicate that resting-state EEG can provide consistent and reproducible measures of brain activity in individuals with FXS. This supports the potential use of EEG as an objective biomarker for evaluating the effects of new drugs in FXS.

Significance: The reliable measurements obtained from power spectrum-based resting-state EEG make it a promising tool for assessing the impact of small molecule drugs in FXS.

Citing Articles

Validating brain activity measures as reliable indicators of individual diagnostic group and genetically mediated sub-group membership Fragile X Syndrome.

Ethridge L, Pedapati E, Schmitt L, Norris J, Auger E, De Stefano L Sci Rep. 2024; 14(1):22982.

PMID: 39362936 PMC: 11450163. DOI: 10.1038/s41598-024-72935-6.

Validating brain activity measures as reliable indicators of individual diagnostic group and genetically mediated sub-group membership Fragile X Syndrome.

Ethridge L, Pedapati E, Schmitt L, Norris J, Auger E, De Stefano L Res Sq. 2024; .

PMID: 38313274 PMC: 10836101. DOI: 10.21203/rs.3.rs-3849272/v1.

References

Knoth I, Vannasing P, Major P, Michaud J, Lippe S . Alterations of visual and auditory evoked potentials in fragile X syndrome. Int J Dev Neurosci. 2014; 36:90-7. DOI: 10.1016/j.ijdevneu.2014.05.003. View

van der Molen M, van der Molen M . Reduced alpha and exaggerated theta power during the resting-state EEG in fragile X syndrome. Biol Psychol. 2012; 92(2):216-9. DOI: 10.1016/j.biopsycho.2012.11.013. View

Pieretti M, Zhang F, Fu Y, Warren S, Oostra B, Caskey C . Absence of expression of the FMR-1 gene in fragile X syndrome. Cell. 1991; 66(4):817-22. DOI: 10.1016/0092-8674(91)90125-i. View

Shou G, Mosconi M, Wang J, Ethridge L, Sweeney J, Ding L . Electrophysiological signatures of atypical intrinsic brain connectivity networks in autism. J Neural Eng. 2017; 14(4):046010. PMC: 5737951. DOI: 10.1088/1741-2552/aa6b6b. View

McCullagh E, Rotschafer S, Auerbach B, Klug A, Kaczmarek L, Cramer K . Mechanisms underlying auditory processing deficits in Fragile X syndrome. FASEB J. 2020; 34(3):3501-3518. PMC: 7347277. DOI: 10.1096/fj.201902435R. View

Lovelace J, Ethell I, Binder D, Razak K . Translation-relevant EEG phenotypes in a mouse model of Fragile X Syndrome. Neurobiol Dis. 2018; 115:39-48. PMC: 5969806. DOI: 10.1016/j.nbd.2018.03.012. View

Einfeld S, Hall W . Behavior phenotype of the fragile X syndrome. Am J Med Genet. 1992; 43(1-2):56-60. DOI: 10.1002/ajmg.1320430108. View

Berry-Kravis E, Krause S, Block S, Guter S, Wuu J, Leurgans S . Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol. 2006; 16(5):525-40. DOI: 10.1089/cap.2006.16.525. View

Jonak C, Pedapati E, Schmitt L, Assad S, Sandhu M, DeStefano L . Baclofen-associated neurophysiologic target engagement across species in fragile X syndrome. J Neurodev Disord. 2022; 14(1):52. PMC: 9513876. DOI: 10.1186/s11689-022-09455-9. View

10.

Goswami S, Cavalier S, Sridhar V, Huber K, Gibson J . Local cortical circuit correlates of altered EEG in the mouse model of Fragile X syndrome. Neurobiol Dis. 2019; 124:563-572. PMC: 6371815. DOI: 10.1016/j.nbd.2019.01.002. View

11.

Ip C, Ganz M, Ozenne B, Sluth L, Gram M, Viardot G . Pre-intervention test-retest reliability of EEG and ERP over four recording intervals. Int J Psychophysiol. 2018; 134:30-43. DOI: 10.1016/j.ijpsycho.2018.09.007. View

12.

Knoth I, Lippe S . Event-related potential alterations in fragile X syndrome. Front Hum Neurosci. 2012; 6:264. PMC: 3449440. DOI: 10.3389/fnhum.2012.00264. View

13.

Kaufmann W, Abrams M, Chen W, Reiss A . Genotype, molecular phenotype, and cognitive phenotype: correlations in fragile X syndrome. Am J Med Genet. 1999; 83(4):286-95. View

14.

Loesch D, Huggins R, Bui Q, Taylor A, Hagerman R . Relationship of deficits of FMR1 gene specific protein with physical phenotype of fragile X males and females in pedigrees: a new perspective. Am J Med Genet A. 2003; 118A(2):127-34. DOI: 10.1002/ajmg.a.10099. View

15.

Lovelace J, Wen T, Reinhard S, Hsu M, Sidhu H, Ethell I . Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome. Neurobiol Dis. 2016; 89:126-35. PMC: 4785038. DOI: 10.1016/j.nbd.2016.02.002. View

16.

Erickson C, Kaufmann W, Budimirovic D, Lachiewicz A, Haas-Givler B, Miller R . Best Practices in Fragile X Syndrome Treatment Development. Brain Sci. 2018; 8(12). PMC: 6315698. DOI: 10.3390/brainsci8120224. View

17.

Schmitt L, Li J, Liu R, Horn P, Sweeney J, Erickson C . Altered frontal connectivity as a mechanism for executive function deficits in fragile X syndrome. Mol Autism. 2022; 13(1):47. PMC: 9733336. DOI: 10.1186/s13229-022-00527-0. View

18.

Ethridge L, White S, Mosconi M, Wang J, Byerly M, Sweeney J . Reduced habituation of auditory evoked potentials indicate cortical hyper-excitability in Fragile X Syndrome. Transl Psychiatry. 2016; 6:e787. PMC: 4872406. DOI: 10.1038/tp.2016.48. View

19.

Jonak C, Lovelace J, Ethell I, Razak K, Binder D . Multielectrode array analysis of EEG biomarkers in a mouse model of Fragile X Syndrome. Neurobiol Dis. 2020; 138:104794. PMC: 9038039. DOI: 10.1016/j.nbd.2020.104794. View

20.

Kozono N, Okamura A, Honda S, Matsumoto M, Mihara T . Gamma power abnormalities in a Fmr1-targeted transgenic rat model of fragile X syndrome. Sci Rep. 2020; 10(1):18799. PMC: 7608556. DOI: 10.1038/s41598-020-75893-x. View